Hosted on MSN1mon
William Blair starts Mersana stock with Outperform rating
The analyst from William Blair highlighted that despite previous challenges, such as the discontinuation of Mersana's former lead program, upifitamab rilsodotin (UpRi), the company's next ...
Nasdaq10d
Mersana Therapeutics Reports Positive Initial Phase 1 Data for Emi-Le and Receives Additional Fast Track Designation
Mersana Therapeutics announced promising Phase ... primarily offset by reduced costs related to clinical development activities for UpRi, a discontinued ADC candidate. General and administrative ...
Morningstar10d
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results
March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics ... with manufacturing and clinical development activities for UpRi, reduced employee compensation expenses following the company’s ...